Shots:

• Boehringer Ingelheim acquires AMAL Therapeutics in all-stock transaction for ~$478.5M. AMAL to get $365.9M including up front- clinical- development- regulatory milestones and $112.6M as commercial milestones
• The focus of the acquisition is to develop new therapies for gastrointestinal and lung cancers in combination with AMAL’s KISIMA immunization platform and to foster BI’s immuno-oncology portfolio with the addition of AMAL’s lead vaccine ATP128
• AMAL’s ATP128 is a chimeric recombinant protein vaccine being developed for stage IV colorectal cancer and will be evaluated in combination with BI’s BI754091 in microsatellite stable (MSS) patients with stage IV colorectal cancer under the agreement signed on May’2019

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Swiss Biotech Association